Targeted Therapeutics Market

Targeted Therapeutics Market

  • BCC Research
  • October 2021
  • Pharmaceutical
  • 156 pages

Report Description

Summary:

Cancer was the leading cause of death in 2020, accounting for 10 million deaths, globally. This disease includes multi gene mutations that produce altered proteins controlling the signaling pathway of cells. Usually, proteins encoded by these genes control cell growth, apoptosis, DNA repair, division and checkpoint, creating cancerous cells. But changes in these genes produce altered proteins that enable cancer.

Targeted therapeutics is an emerging and promising approach for oncology treatment, targeting the proteins that stimulate the growth of cancer cells. Small molecules offer more advantages than monoclonal antibodies, targeting molecules inside the cells (along with surface receptors) to modulate protein function.

The dynamic field of cancer R&D offers specialization in targeted therapies, which play a crucial role as mediators in cancer and other diseases, modulating diverse cellular activities.

The market for targeted therapeutics has increasing demand. As the field of targeted therapy matures, market leaders must use technologies and methods for novel targets and therapeutic approaches.

Market Size and Evolution

The global targeted therapeutics market was valued at around REDACTED in 2020 and is expected to reach REDACTED by 2026.

The United States led the market for targeted therapeutics with around REDACTED in sales in 2020. The U.S. market for targeted therapeutics is expected to increase at a CAGR of REDACTED from 2021-2026. The Asia-Pacific region generated nearly REDACTED in sales in 2020 and is expected to grow with the second highest CAGR REDACTED during the forecast period.

The Rest of the World market segment revenue in 2020 was REDACTED and will grow slowly in the coming years. The European market for targeted therapeutics was worth REDACTED in 2020 and will reach REDACTED in 2026. It is forecast to increase at a CAGR of REDACTED through 2026.

Emerging markets, particularly in the Asia-Pacific region, have shown growth potential in recent years. Rising affluence in these countries brings change in lifestyles, resulting in increased incidence of cancer. Developing countries in Africa and elsewhere are still battling some of the highest proportions of immune-mediated diseases. The need for affordable and innovative medicines drives growth in the targeted therapeutics market in the low- and middle-income developing countries.

Report Scope:

The scope of this study entails the worldwide market for targeted therapeutics. The report covers the entire market for targeted therapeutics, which incorporates two main types, small molecules and monoclonal antibodies. Based on application, targeted therapeutics is divided into lung cancer, breast cancer, blood cancer, colorectal cancer and others.

By geography, the market has been divided into four regions: North America, Europe, AsiaPacific and the Rest of the World. Detailed analyses of major countries: the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China and India are covered. For market estimates, data has been provided for the year 2020 as the base year, with forecasts for 20212026. Estimated values are based on drug manufacturer total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Report Includes:

  •  24 data tables and 29 additional tables
  •  An overview of the global market for targeted therapeutics within the biopharmaceuticals sector
  •  Analyses of the global market trends, with data from 20192020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026
  •  Evaluation of current market size and market forecast for targeted therapeutics, technological advancements, and corresponding market share analysis by type, application and geographic region
  •  Detailed description of the targetspecific functionality, advantages of target therapeutics, their production and processes, and discussion on their ability to provide therapeutic treatments for various chronic diseases
  •  Coverage of disease and economic burden of cancer, types of cancer therapy and insights into cancer treatment strategy timeline
  •  Insight into global R&D activities related to oncology drugs, industry structure, product launches, clinical trials, and regulatory scenario affecting the future marketplace
  •  Competitive landscape and pipeline analysis of the key companies operating in the global market, their company share analysis, and relevant oncology drug licensing deals and M&A deals
  •  Company profiles of major industry players, including Amgen Inc., AstraZeneca, Boehringer Ingelheim, BristolMyers Squibb (BMS), F. HoffmannLa Roche Ltd., Pfizer, Novartis, Merck & Co., and Takeda Pharmaceutical Co., Ltd.

Countries Covered

  • United States

Keywords

  • Targeted Therapeutics Market

Have query on this report?

Make an Enquiry

Table of Contents

Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Intended Audience
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

Chapter 2 Summary and Highlights
Market Size and Evolution

Chapter 3 Market Overview
Cancer Burden
Causes of Cancer
Genetic Factors
Lifestyle Factors
Environmental Factors
Cancer-Causing Genes
Immune System and Cancer
Cancer Prevention
Types of Cancer Treatment
Non-pharmacological Approaches
Pharmacological Approaches
Gene Therapy
Market Dynamics
Drivers
Restraints
Opportunity

Chapter 4 Impact of COVID-19 on Market
Overview
Current Outlook
Impact of COVID-19 on Cancer Care

Chapter 5 Regulatory Aspects
Overview
United States
New Drug Application (NDA)
Fast-Track Status
Europe
Japan
India
New Drug Approval
Import Registration Certificate
Import License
China

Chapter 6 Market Breakdown by Type of Targeted Therapy
Overview
Small Molecules
Market Size and Forecast
Market Analysis
Monoclonal Antibodies
Market Size and Forecast
Market Analysis

Chapter 7 Market Breakdown by Application
Overview
Lung Cancer
Market Size and Forecast
Market Analysis
Breast Cancer
Market Size and Forecast
Market Analysis
Blood Cancer
Market Size and Forecast
Market Analysis
Colorectal Cancer
Market Size and Forecast
Market Analysis
Other Cancers
Market Size and Forecast
Market Analysis

Chapter 8 Market Breakdown by Region
Introduction
North America
Market Analysis
U.S.
Canada
Europe
Market Impact
Germany
U.K.
France
Italy
Spain
Rest of Europe
Asia-Pacific
Market Analysis
China
India
Japan
Rest of Asia-Pacific
Rest of the World
Market Size and Forecast

Chapter 9 Industry Structure
Company Landscape
Pipeline Analysis
Phase I Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials
Phase IV Clinical Trials

Chapter 10 Company Profiles
AMGEN INC.
ASTRAZENECA
BAYER AG
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BRISTOL-MYERS SQUIBB
F. HOFFMANN-LA ROCHE LTD.
MERCK & CO., INC.
NOVARTIS AG
PFIZER
TAKEDA PHARMACEUTICAL CO., LTD
.
Chapter 11 Appendix: Acronyms

List of Tables

Summary Table : Global Market for Targeted Therapeutics, by Type, Through 2026
Table 1 : Cancer Treatment Types
Table 2 : Cancer Treatment Strategy Timeline
Table 3 : List of Cancer Drug/Imaging Agent Approvals, 2020
Table 4 : Patent Expiration Dates, Targeted Therapy Drugs
Table 5 : Side Effects of Targeted Therapies
Table 6 : Coronavirus Reported Cases and Deaths, by Country, 2020
Table 7 : FDA Approval Date, Selected Targeted Therapeutic Drugs
Table 8 : Global Market for Targeted Therapeutics, by Type, Through 2026
Table 9 : Global Market for Cancer Small Molecule Therapy, by Region, Through 2026
Table 10 : Selected Small Molecule Inhibitors for Cancer Therapy
Table 11 : Global Market for Cancer Monoclonal Antibody Therapy, by Region, Through 2026
Table 12 : Selected Approved/Under-Review MAB Cancer Therapeutics in the U.S. and EU
Table 13 : Global Market for Targeted Therapeutics, by Application, Through 2026
Table 14 : Global Market for Targeted Therapeutics for Lung Cancer, by Region, Through 2026
Table 15 : Some Targeted Therapeutics for Lung Cancer
Table 16 : Global Market for Targeted Therapeutics for Breast Cancer, by Region, Through 2026
Table 17 : Global Market for Targeted Therapeutics for Blood Cancer, by Region, Through 2026
Table 18 : Global Market for Targeted Therapeutics for Colorectal Cancer, by Region, Through 2026
Table 19 : Global Market for Targeted Therapeutics for Other Types of Cancer, by Region, Through 2026
Table 20 : Global Market for Targeted Therapeutics, by Region, Through 2026
Table 21 : North American Market for Targeted Therapeutics, by Type, Through 2026
Table 22 : North American Market for Targeted Therapeutics, by Application, Through 2026
Table 23 : North American Market for Targeted Therapeutics, by Country, Through 2026
Table 24 : European Market for Targeted Therapeutics, by Type, Through 2026
Table 25 : European Market for Targeted Therapeutics, by Application, Through 2026
Table 26 : European Market for Targeted Therapeutics, by Country, Through 2026
Table 27 : Asia-Pacific Market for Targeted Therapeutics, by Type, Through 2026
Table 28 : Asia-Pacific Market for Targeted Therapeutics, by Application, Through 2026
Table 29 : Asia-Pacific Market for Targeted Therapeutics, by Country, Through 2026
Table 30 : Rest of the World Market for Targeted Therapeutics, by Type, Through 2026
Table 31 : Rest of the World Market for Targeted Therapeutics, by Application, Through 2026
Table 32 : Revenue: Selected Targeted Therapeutics, 2019 and 2020
Table 33 : Oncology Drug Licensing Deals, 2020
Table 34 : Oncology Merger and Acquisition Deals, 2020
Table 35 : Selected Targeted Therapeutics in Phase I Clinical Trials, 2021
Table 36 : Selected Targeted Therapeutics in Phase II Clinical Trials, 2021
Table 37 : Selected Targeted Therapeutics in Phase III Clinical Trials, 2021
Table 38 : Selected Targeted Therapeutics in Phase IV Clinical Trials, 2021
Table 39 : Amgen Inc.: Marketed Products, 2020
Table 40 : AstraZeneca: Marketed Products, 2020
Table 41 : Bayer AG: Marketed Products, 2020
Table 42 : Boehringer Ingelheim International GmbH: Marketed Products, 2020
Table 43 : Bristol-Myers Squibb: Marketed Products, 2020
Table 44 : Bristol-Myers Squibb: Selected Product Approvals, 2020-2021
Table 45 : F. Hoffmann-La Roche Ltd.: Marketed Products, 2020
Table 46 : Merck & Co., Inc.: Marketed Products, 2020
Table 47 : Merck & Co., Inc.: Selected Product Approvals, 2020
Table 48 : Novartis AG: Marketed Products, 2020
Table 49 : Pfizer: Marketed Products, 2020
Table 50 : Takeda Pharmaceutical Co., Ltd.: Marketed Products, 2020
Table 51 : Takeda Pharmaceutical Co., Ltd.: Selected Product Approval, 2020-2021
Table 52 : Acronyms Used in This Report

Success Stories

Our Clients